Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single arm, phase II trial in young patients (18-60
years) with poor-prognosis (aaIPI 2 or 3) newly diagnosed Diffuse Large B-cell Lymphoma
(DLBCL).
Aim of the study is to assess the efficacy and the safety of G-CHOP in combination with
ibrutinib.